Andreano E. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell. 2021. doi:10.1016/j.cell.2021.02.035 [Epub ahead of print]
Chen P, Nirula A, Heller B, et al; BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384:229-237.
Clinical Trials Arena. Lilly’s bamlanivimab prevents Covid-19 at nursing homes in BLAZE-2 trial. News Release. January 22, 2021. https://www.clinicaltrialsarena.com/news/lilly-bamlanivimab-nursing-homes/ Accessed March 25, 2021.
ClinicalTrials.gov. Efficacy and safety of TY027, a treatment for COVID-19, in humans. NCT04649515. Updated December 14, 2020. Accessed March 3, 2021. https://clinicaltrials.gov/ct2/show/NCT04649515
ClinicalTrials.gov. Phase III double-blind, placebo-controlled study of AZD7442 for post-exposure prophylaxis of COVID-19 in adults (STORM CHASER). NCT04625972. Updated January 11, 2021. Accessed March 3, 2021. https://clinicaltrials.gov/ct2/show/NCT04625972
Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, et al. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62-75.
DeFrancesco L. COVID-19 antibodies on trial. Nat Biotechnol. 2020;38:1242-1252.
European Medicines Agency (EMA). EMA issues advice on use of REGN-COV2 antibody combination (casirivimab / imdevimab). News release. February 26, 2021. Accessed March 3, 2021. https://www.ema.europa.eu/en/news/ema-issues-advice-use-regn-cov2-antibody-combination-casirivimab-imdevimab
European Medicines Agency (EMA). EMA issues advice on use of regdanvimab for treating COVID-19. News release. March 26, 2021. Accessed March 26, 2021. https://www.ema.europa.eu/en/news/ema-issues-advice-use-regdanvimab-treating-covid-19
European Medicines Agency (EMA). EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19. News release. February 24, 2021. Accessed March 3, 2021. https://www.ema.europa.eu/en/news/ema-starts-rolling-review-celltrion-antibody-regdanvimab-covid-19
European Medicines Agency (EMA). EMA starts rolling review of Eli Lilly antibodies bamlanivimab and etesevimab for COVID-19. News release. March 11, 2021. Accessed March 23, 2021. https://www.ema.europa.eu/en/news/ema-starts-rolling-review-eli-lilly-antibodies-bamlanivimab-etesevimab-covid-19
European Pharmaceutical Review. REGEN-COV prevents symptomatic COVID-19 infections, finds analysis. News Release. January 27, 2021. https://www.europeanpharmaceuticalreview.com/news/141049/regen-cov-prevents-symptomatic-covid-19-infections-finds-analysis Accessed March 25, 2021.
FDA. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19. News release. February 9, 2021. Accessed March 3, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19-0
FDA. Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab and etesevimab. Published February 9, 2021. Accessed March 3, 2021. https://www.fda.gov/media/145802/download
FDA. Fact sheet for health care providers emergency use authorization (EUA) of casirivimab and imdevimab. Revised December 2020. Accessed March 3, 2021. https://www.fda.gov/media/143892/download
Griffin MP, Yuan Y, Takas T, et al; Nirsevimab Study Group. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383:415-425.
Jaworski JP, Cahn P. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1. Lancet HIV. 2018;5:e723-e731.
Jimenez D. South Korea approves Celltrion's COVID-19 treatment regdanvimab for emergency use. Pharmafile. February 8, 2021. Accessed March 3, 2021. http://www.pharmafile.com/news/570691/south-korea-approves-celltrions-covid-19-treatment-regdanvimab-emergency-use
Lee G. Celltrion shares positive phase I results and plans for anti-COVID-19 antibody CT-P59. BioWorld™. November 9, 2020. Accessed March 3, 2021. https://www.bioworld.com/articles/499959-celltrion-shares-positive-phase-i-results-and-plans-for-anti-covid-19-antibody-ct-p59
Levine MM. Monoclonal antibody therapy for Ebola virus disease. N Engl J Med. 2019;12;381:2365-2366.
Lloyd EC, Gandhi TN, Petty LA. Monoclonal antibodies for COVID-19. JAMA. 2021;325:1015.
Low JG, Ng JHJ, Ong EZ, et al. Phase 1 trial of a therapeutic anti-yellow fever virus human antibody. N Engl J Med. 2020;383:452-459.
Marovich M, Mascola JR, Cohen, MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020;324:131-132.
Mulangu S, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381:2293-2303.
National Research Council (US) Committee on Methods of Producing Monoclonal Antibodies. Large-scale production of monoclonal antibodies. In: Monoclonal Antibody Production. Washington (DC):National Academies Press (US);1999.
Nelson PN, Reynolds GM, Waldron EE, et al. Monoclonal antibodies. Mol Pathol. 2000;53:111-117.
The Pharma Letter. Lilly, GSK and Vir join forces to trial bamlanivimab and VIR-7831 for COVID-19. New release. January 28, 2021.
https://www.thepharmaletter.com/article/lilly-gsk-and-vir-join-forces-to-trial-bamlanivimab-and-vir-7831-for-covid-19 Accessed March 25, 2021.
PMLive. Celltrion’s investigational mAb cuts COVID-19 recovery time. News release. January 14, 2021.
http://www.pmlive.com/pharma_news/celltrions_investigational_mab_cuts_covid-19_recovery_time_1361284 Accessed March 25, 2021.
San-Juan-Rodriguez A, et al. Pricing of monoclonal antibodies in the United States. Glob J Qual Saf Healthc. 2018;1:4-5.
Schoof M, et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020;370:1473-1479.
Tuccori M. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs. 2020;12:1854149.
Weinreich DM, Sivapalasingam S, Norton T, et al; Trial Investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384:238-251.
Yang L, Liu W, Yu X, et al. COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antib Ther. 2020;3:205-212.
Yu X, Cragg MS. Engineered antibodies to combat viral threats. Nature. 2020;588:398-399.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Michel D. Kazatchkine, MD

Special Advisor, Joint United Nations Program on AIDS (UNAIDS) in Eastern Europe and Central Asia
Senior Fellow, Global Health Center,
The Graduate Institute of International and Development Studies
Geneva, Switzerland

Disclosures

Disclosure: Michel D. Kazatchkine, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ExeVir Bio
Owns stock, stock options, or bonds from: ExeVir Bio

Michel Goldman, MD

Founder and Co-Director
I3h Institute
Université libre de Bruxelles
Brussels, Belgium

Disclosures

Disclosure: Michel Goldman, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: OneLife SA; Vésale Pharma SA
Other: Michel Consult SPTL

Michael G. Ison, MD

Professor of Medicine
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States

Disclosures

Disclosure: Michael G. Ison, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Adagio; AlloVir; Celltrion Healthcare; Cidara Therapeutics, Inc.; Eurofins Viracor, Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Shionogi & Co., Ltd.; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: AiCuris; Janssen Pharmaceuticals, Inc.; Shire

Editor

Gillian Griffith, BA (Mod), MA

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Gillian Griffith, BA (Mod), MA, has disclosed no relevant financial relationships.

CPD

Monoclonal Antibody Therapeutics for SARS-CoV-2

Authors: Michel D. Kazatchkine, MD; Michel Goldman, MD; Michael G. Ison, MD
CPD Released: 3/29/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 3/29/2022

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US rheumatologists, clinical immunologists, and infectious disease specialists.

The goal of this activity is to provide an overview of antibody therapeutics for SARS-CoV-2.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Rationale for the development of neutralizing antibody therapeutics for COVID-19
- Clinical trial data for monoclonal antibodies against SARS-CoV-2

Disclosures

Faculty

Michel D. Kazatchkine, MD

Special Advisor, Joint United Nations Program on AIDS (UNAIDS) in Eastern Europe and Central Asia
Senior Fellow, Global Health Center,
The Graduate Institute of International and Development Studies
Geneva, Switzerland

Disclosures

Disclosure: Michel D. Kazatchkine, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ExeVir Bio
Owns stock, stock options, or bonds from: ExeVir Bio

Michel Goldman, MD

Founder and Co-Director
I3h Institute
Université libre de Bruxelles
Brussels, Belgium

Disclosures

Disclosure: Michel Goldman, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: OneLife SA; Vésale Pharma SA
Other: Michel Consult SPTL

Michael G. Ison, MD

Professor of Medicine
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States

Disclosures

Disclosure: Michael G. Ison, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Adagio; AlloVir; Celltrion Healthcare; Cidara Therapeutics, Inc.; Eurofins Viracor, Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Shionogi & Co., Ltd.; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: AiCuris; Janssen Pharmaceuticals, Inc.; Shire

Editor

Gillian Griffith, BA (Mod), MA

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Gillian Griffith, BA (Mod), MA, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

Biosimilars in Immune-Mediated Diseases

From Medscape Education

CPD

Monoclonal Antibody Therapeutics for SARS-CoV-2

Authors: Michel D. Kazatchkine, MD; Michel Goldman, MD; Michael G. Ison, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 3/29/2021

Valid for credit through: 3/29/2022

processing....

Note: The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available. In order to facilitate disseminating this educational activity as quickly as possible, the associated slides will be included 1 to 2 weeks after the activity posting date.

CPD Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of WebMD Global, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Michel D. Kazatchkine, MD

Michel Goldman, MD

Michael G. Ison, MD

Editor

Gillian Griffith, BA (Mod), MA

CPD

Monoclonal Antibody Therapeutics for SARS-CoV-2

Target Audience and Goal Statement

Disclosures

Faculty

Michel D. Kazatchkine, MD

Michel Goldman, MD

Michael G. Ison, MD

Editor

Gillian Griffith, BA (Mod), MA

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Monoclonal Antibody Therapeutics for SARS-CoV-2